



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/775,510	02/10/2004	Denise Marie Beachy	J3711(C)	1049
201	7590	02/02/2009	EXAMINER	
UNILEVER PATENT GROUP			CHUI, MEI PING	
800 SYLVAN AVENUE				
AG West S. Wing			ART UNIT	PAPER NUMBER
ENGLEWOOD CLIFFS, NJ 07632-3100			1616	
			MAIL DATE	DELIVERY MODE
			02/02/2009	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/775,510	BEACHY ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	MEI-PING CHUI	1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 13 August 2008.  
 2a) This action is **FINAL**.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1 and 3-24 is/are pending in the application.  
 4a) Of the above claim(s) 3,5,9-11,13-15,17 and 21 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1,4,6-8,12,16,18-20 and 22-24 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>08/13/2008</u> .	6) <input type="checkbox"/> Other: _____ .

**DETAILED ACTION**

***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/13/2008 has been entered.

***Status of Action***

Receipt of Amendments/Remarks filed on 08/13/2008 is acknowledged. Claims 1 and 4 have been amended; claim 2 has been cancelled; claims 3, 5, 9-11, 13-15, 17 and 21 have been withdrawn.

***Status of Claims***

Accordingly, claims 1, 4, 6-8, 12, 16, 18-20 and 22-24 are presented for examination on the merits for patentability.

***DOUBLE PATENTING***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible

harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

**Claims 1, 6-8, 12, 16, 18-20 and 22-23 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-43 and 48-51 of co-pending U.S. Patent Application No. 11/316,596.**

Instant claim 1 is directed to an anhydrous antiperspirant composition comprising: (i) a particulate antiperspirant active, (ii) a water-immiscible carrier fluid comprises an aryl substituted siloxane and, (iii) a gellant or structurant for the carrier fluid.

Conflicting claim 1 of co-pending U. S. Patent Application No. 11/316,596 also is directed to an anhydrous antiperspirant composition comprising: (i) a particulate antiperspirant active, (ii) a water-immiscible carrier fluid comprises non-volatile silicone oil, and (iii) a fiber-forming amide gellant.

Instant and conflicting claim 1 differ in that the instant claim 1 recites the carrier fluid comprises an aryl substituted siloxane which satisfies the general formula 1:  $R^1R^A_2Si-O-[SiR^2R^A-O]_n-SiR^3R^A_2$ , in which n = 0 to 2 and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> each independently represents R<sup>4</sup> (diphenylethyl group); but the conflicting claim 1 recites the carrier fluid comprises a non-volatile silicone oil. However, conflicting claim 9 of the co-pending application further recites that the non-volatile silicone oil, according to claim 1, comprises an aryl substituted siloxane which satisfied the general formula:  $R^1R^A_2Si-O-[SiR^2R^A-O]_n-SiR^3R^A_2$ , in which n = 0 to 2 and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> each independently represents R<sup>4</sup> of the formula –CH<sub>2</sub>-C(Ph)(R<sup>B</sup>)(R<sup>5</sup>)(Ph), wherein R<sup>B</sup> is H and R<sup>5</sup> is zero.

Therefore, one of ordinary skill in the art, at the time the claimed invention was made, would have readily recognized that claims 1, 16, 18-20 and 22-23 in the instant application embrace the claims 1-43 and 48-51 of co-pending U.S. Patent Application No. 11/316,596, thus they are not patentability distinct.

#### ***Response to Arguments***

Applicants' arguments filed on 08/13/2008 have been fully considered but they are not persuasive.

Applicants argue that the provisional rejection on the ground of nonstatutory obviousness-type double patenting over the copending U. S. Patent Application No. 11/316,596 is premature, and in any event, would more properly be made in the later filed application (see Remarks: page 7).

The arguments are not persuasive because the "provisional" double patenting rejection should continue to be made by the examiner in each application as long as there are conflicting claims in more than one application unless that "provisional" double patenting rejection is the only rejection remaining in one of the applications." See MPEP 822.01. Since the double patenting rejection is not the only rejection in the instant application; therefore, the double patenting rejection is Maintained.

***Claim Rejections - 35 USC § 112 second paragraph***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 12 is indefinite because it recites that "A composition according to claim 1, in which the aryl substituted siloxane comprises at least 50% by weight of the carrier fluid or mixture of fluids"; however, the recitation in claim 1 is that "the carrier fluid comprises an aryl

substituted siloxane”, which means the aryl substituted siloxane is a part of, or comprised in, the carrier fluid. Applicant is required to clarify the recitation of claim 12.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

**Claims 1, 6-8, 12, 16, 18-20 and 22-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over McGlone et al. (U. S. Patent No. 6,503,492) in view of Chuah et al. (U. S. Patent Application Publication No. 2004/0213748, which is equivalent to WO 03/005977, published on 01/23/2003).**

***Applicant Claims***

Applicants claim an anhydrous antiperspirant composition comprising (i) a particulate antiperspirant active, i.e. aluminum/zirconium chlorohydrate complex with amino acid, (ii) a water-immiscible carrier fluid comprises an aryl substituted siloxane, wherein the carrier fluid comprises an aryl substituted siloxane which satisfies the general formula 1:  $R^1R^A_2Si-O-[SiR^2R^A-O]_n-SiR^3R^A_2$ , in which n = 0 to 2 and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> each independently represents R<sup>4</sup> (diphenylethyl group), and (iii) a gellant or structurant for the carrier fluid, i.e. N-acyl amino acid amides and esters.

***Determination of the scope and content of the prior art***

***(MPEP 2141.01)***

McGlone et al. teach an antiperspirant cosmetic composition, suitable for topical application, comprising (i) an antiperspirant active, i.e. an aluminium/zirconium complex, (ii) a carrier for the antiperspirant active (column 3, lines 15-21). More specifically, McGlone et al. teach that the antiperspirant active can be aluminum/zirconium complexes, i.e. aluminum/zirconium chlorohydrate complex with glycine, which presents from 1 % to 35 % by weight of the composition (column 5, lines 12-29; column 14, line 34; and Table 10, lines 33-34 and 58).

McGlone et al. also teach that the antiperspirant active can be present in particulate form, whereupon it is suspended in a suitable water-immiscible carrier fluid, and which can be structured or thickened to produce a cream (soft solid) or solid (column 5, lines 31-34 and column 6, lines 12-16). In addition, McGlone et al. teach that the carrier material, which can be a fluid or a mixture of fluid, is often selected according to the physical form of the cosmetic composition and can be selected to provide desirable physical and sensory properties, i.e.

moisturizing effect, for the cosmetic products (column 6, lines 21-23 and 25-26). Carrier materials, which act as emollients, can be volatile or non-volatile, and can be present in an amount of 5 % to 90 % by weight of the composition (column 5, line 62-64, and column 6, lines 21-22). McGlone et al. teach that non-volatile silicones, i.e. polyalkylarylsiloxanes including polymethylphenylsiloxanes, are useful as carrier materials to provide desirable properties (column 6, lines 54-58).

McGlone et al. further teach that the structurant can be a fiber-forming gellant, i.e. N-acyl amino acid amides and esters, which includes N-lauroyl-L-glutamic acid di-n-butylamide or lanosterol (column 7, lines 20-24), presents in an amount from 0.1 to 25 %, preferably from 1 % to 15 % by weight (column 7, lines 47-55). However, McGlone et al. also teach that the amount of structurant that can be employed will depend upon the viscosity of a fluid formulation and the hardness of the formulation the manufacturer wishes to attain (column 7, lines 47-50).

*Ascertainment of the difference between the prior art and the claims*  
*(MPEP 2141.02)*

(1) Although, McGlone et al. teach the water-immiscible carrier fluid can be non-volatile polyalkylarylsiloxanes; however, McGlone et al. do not specifically teach that the siloxane carrier is substituted with diphenyethyl group. (2) McGlone et al. also do not teach the antiperspirant composition has hardness at least 0.003 N/mm<sup>2</sup> by sphere indentation. These deficiencies are cured by the teaching of Chuah et al.

Chuah et al. teach an anhydrous antiperspirant formulation, in the form of a soft solid, comprising (i) a particulate antiperspirant active present from 5 % to 30 % by weight, (ii) an

Art Unit: 1616

anhydrous carrier fluid in an amount of from 50 % to 85 % by weight, and (iii) a structurant system for the anhydrous carrier fluid (page 1: [0007-0008]).

Chuah et al. teach that the soft solid formulation is capable of being extruded through a narrow aperture in a dispenser head under application of low pressure and has a hardness of from  $3 \times 10^{-3}$  N/mm<sup>2</sup> (0.003 N/mm<sup>2</sup>) as measured by a sphere indentation technique (page 1: [0012]).

Chuah et al. also teach that the carrier fluid used in the antiperspirant formulation can be non-volatile silicone oils, i.e. linear silicone oils which contain a high proportion of phenyl substituents (page 3: [0035], lines 6-8).

Chuah et al. further teach that the structurant system for the anhydrous carrier fluid can comprise a co-structurant, which preferably is a fiber-forming structurant including N-acyl amino acid amides and esters, i.e. N-lauroyl-L-glutamic acid di-n-butylamide (page 4: [0065]-[0073]).

Chuah et al. teach that suitable antiperspirant actives, i.e. aluminium/zirconium chlorohydrates complex with an amino acid glycine, can be used in the formulation (page 7: [0099], [0103-0104]). Chuah et al. also teach that some antiperspirant actives are produced in the form of dense particles and some are produced in the form of hollow particles that have been milled; however, the selection of the one with dense particles or the one with hollow particles is depended on the desired formulation whether is a translucent formulation or is an opaque formulation (page 7: [0105]).

Importantly, Chuah et al. teach that a significant factor in determining whether a formulation is translucent or opaque is the difference between the refractive index of the carrier

mixture and that of the suspended antiperspirant salt. The mismatch in refractive index can be controlled by a number of treatments to the antiperspirant active and by suitable selection of the carrier fluids (page 7, [0109]). Chuah et al. teach that one way to increase the refractive index of the silicone carrier fluid is by increasing the proportion of aromatic contents relative to aliphatic content (page 7, [0109]). Chuah et al. then teach that even though if the refractive index of the carrier fluid and the suspended antiperspirant active do not match exactly, as long as the refractive index difference between these two constituents falls within the range of 0.003 to 0.08 units, translucency on extrusion through narrow apertures can be obtained. Therefore, it is desirable that the mismatch be minimized within the range of not more than 0.11 units (page 7: [0110]).

*Finding of prima facie obviousness Rational and Motivation*

*(MPEP 2142-2143)*

It would have been obvious to a person of ordinary skilled in the art at the time the invention was made to combine the teaching of McGlone et al. and Chuah et al. to arrive at the instant invention.

One of ordinary skill would have been motivated to follow the guidance of McGlone et al. and Chuah et al. to produce an antiperspirant composition, which comprises an antiperspirant active aluminium/zirconium complex and a water-immiscible alkylarylsiloxane carrier fluid that provides desirable cosmetic effects. One of ordinary skill in the art also would have been motivated to modify the refractive index of the alkylarylsiloxane carrier fluid to a desired level by increasing the aromatic content of the carrier fluid, so that it can closely match with the

refractive index of the selected antiperspirant active based on the desired optical clarity of the antiperspirant product, as taught by Chuah et al.

In addition, one of ordinary skill would also have been motivated to adjust the amount of structurant to a desirable level to obtain the suitable hardness, dependent upon the viscosity of a fluid formulation and the hardness of the desirable product form, i.e. soft solid, spray, liquid or cream, the manufacturer wishes to attain, as taught by McGlone et al.

The combine references teach the claimed antiperspirant composition with the concept of increasing the number of aryl group in the structure of a siloxane carrier fluid would increase its refractive index, and the refractive index matching between an antiperspirant active and a carrier fluid would affect the transparency property; therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

**Claim 4 is rejected under 35 U. S. C. 103(a) as being unpatentable over McGlone et al. (U. S. Patent No. 6,503,492) and Chuah et al. (U. S. Patent Application Publication No. 2004/0213748) combined, and in view of Nye et al. (WO 00/27348).**

*Applicants Claim*

Applicants claim an anhydrous antiperspirant composition comprising (i) a particulate antiperspirant active, (ii) a water-immiscible carrier fluid comprises an aryl substituted siloxane, wherein the carrier fluid comprises an aryl substituted siloxane which satisfies the general formula 1:  $R^1R^A_2Si-O-[SiR^2R^A-O]_n-SiR^3R^A_2$ , in which n = 0 to 2 and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> each

independently represents a capping group:  $\alpha$ -methylstyrene dimer ( $R^c$ ) and (iii) a gellant or structurant for the carrier fluid.


***Determination of the scope and content of the prior art***  
***(MPEP 2141.01)***

The teachings of McGlone et al. and Chuah et al. have been set forth above. Essentially, McGlone et al. and Chuah et al. teach an antiperspirant composition comprising an antiperspirant active and non-volatile alkylarylsiloxane carrier materials for suspending the antiperspirant active.

***Ascertainment of the difference between the prior art and the claims***  
***(MPEP 2141.02)***

McGlone et al. and Chuah et al. do not teach that the alkylarylsiloxane carrier materials are substituted with a residue of  $\alpha$ -methyl styrene dimer. However, the deficiency is cured by the teaching of Nye et al.

Nye et al. teach a personal care composition comprising an aralkylsiloxane component to enhance the shine, emolliency and lubricity properties of the personal care composition, as well as aids in visually masking the inorganic components comprised in the composition (page 1: lines 112-17). Nye et al. teach the aralkylsiloxane component has a structure as follows:



Nye et al. also teach that the aralkylsiloxane component is made by contacting a silylhydride-functional polysiloxane with a terminally unsaturated arylalkene, i.e. styrene, to

produce an aralkylsiloxane containing  $\alpha$ -methyl styrene group in the structure (page 2: formula I; page 5: lines 19-23 and page 8: Example). Nye et al. also teach that the aralkyl content of the aralkylsiloxane is selected to provide a refractive index of from 1.40 to 1.50 (page 5: lines 9-15).

***Finding of prima facie obviousness Rational and Motivation***  
***(MPEP 2142-2143)***

It would have been obvious to a person of ordinary skilled in the art at the time the invention was made to follow the guidance of McGlone et al. and Chuah et al., and further in view of Nye et al. to arrive at the instant invention.

One of ordinary skill would have been motivated to utilize arylalkenes, i.e. styrene group, to produce an aralkylsiloxane compound containing  $\alpha$ -methyl styrene residue(s) in the structure, dependent on the desired refractive index of the aralkylsiloxane compound the producer wishes to attain.

From the teaching of the references, one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

***Conclusion***

No claims are allowed.

***Contact Information***

Any inquiry concerning this communication from the Examiner should direct to Helen Mei-Ping Chui whose telephone number is 571-272-9078. The examiner can normally be reached on Monday-Friday (7:30 am – 5:00 pm). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where the application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either PRIVATE PAIR or PUBLIC PAIR. Status information for unpublished applications is available through PRIVATE PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the PRIVATE PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/H. C./

Examiner, Art Unit 1616

/Mina Haghigian/  
Primary Examiner, Art Unit 1616